Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent.

MLA

Erlinge, David, et al. “Rationale and Design of INFINITY-SWEDEHEART: A Registry-Based Randomized Clinical Trial Comparing Clinical Outcomes of the Sirolimus-Eluting DynamX Bioadaptor to the Zotarolimus-Eluting Resolute Onyx Stent.” American Heart Journal, vol. 277, Nov. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1016/j.ahj.2024.07.016.

APA

Erlinge, D., Andersson, J., Fröbert, O., Törnerud, M., Böhm, F., Held, C., Elek, C., Sirhan, M., Oldgren, J., & James, S. (2024). Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent. American Heart Journal, 277, 1–10. https://doi.org/10.1016/j.ahj.2024.07.016

Chicago

Erlinge, David, Jonas Andersson, Ole Fröbert, Mattias Törnerud, Felix Böhm, Claes Held, Candace Elek, Motasim Sirhan, Jonas Oldgren, and Stefan James. 2024. “Rationale and Design of INFINITY-SWEDEHEART: A Registry-Based Randomized Clinical Trial Comparing Clinical Outcomes of the Sirolimus-Eluting DynamX Bioadaptor to the Zotarolimus-Eluting Resolute Onyx Stent.” American Heart Journal 277 (November): 1–10. doi:10.1016/j.ahj.2024.07.016.